Overview

Efficacy Study of Iguratimod Combined With Tofacitab in Patients With RF Positive/Negative Rheumatoid Arthritis

Status:
Recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
Rheumatoid arthritis (RA) is a chronic progressive autoimmune disease with predominantly joint involvement. To compare the efficacy and difference between elamod and tofacitib in the treatment of rheumatoid factor-positive and negative rheumatoid arthritis in RA patients with poor outcome after csDMARDs dosing, in order to better inform the clinical management.
Phase:
Phase 4
Details
Lead Sponsor:
Yanfeng Hou
Treatments:
Tofacitinib